Cargando…

What could health technology assessment learn from living clinical practice guidelines?

A “living” approach to clinical practice guidelines is when the identification, appraisal and synthesis of evidence is maintained and repeated at an agreed frequency, with a clear process for when and how new evidence is to be incorporated. The value of a living approach to guidelines was emphasised...

Descripción completa

Detalles Bibliográficos
Autores principales: Cheyne, Saskia, Chakraborty, Samantha, Lewis, Samara, Campbell, Sue, Turner, Tari, Norris, Sarah
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10484706/
https://www.ncbi.nlm.nih.gov/pubmed/37693902
http://dx.doi.org/10.3389/fphar.2023.1234414
_version_ 1785102640475013120
author Cheyne, Saskia
Chakraborty, Samantha
Lewis, Samara
Campbell, Sue
Turner, Tari
Norris, Sarah
author_facet Cheyne, Saskia
Chakraborty, Samantha
Lewis, Samara
Campbell, Sue
Turner, Tari
Norris, Sarah
author_sort Cheyne, Saskia
collection PubMed
description A “living” approach to clinical practice guidelines is when the identification, appraisal and synthesis of evidence is maintained and repeated at an agreed frequency, with a clear process for when and how new evidence is to be incorporated. The value of a living approach to guidelines was emphasised during the COVID-19 pandemic when health professionals and policymakers needed to make decisions regarding patient care in the context of a nascent but rapidly evolving evidence base. In this perspective, we draw on our recent experience developing Australian and international living guidelines and reflect on the feasibility of applying living guideline methods and processes to a lifecycle approach to health technology assessment (HTA). We believe the opportunities and challenges of adopting a living approach in HTA fall into five key themes: identification, appraisal and synthesis of evidence; optimising the frequency of updates; embedding ongoing multi-stakeholder engagement; linking the emergence of new evidence to reimbursement; and system capacity to support a living approach. We acknowledge that the suitability of specific living approaches to HTA will be heavily influenced by the type of health technology, its intended use in the health system, local reimbursement pathways, and other policy settings. But we believe that the methods and processes applied successfully to guideline development to manage evidentiary uncertainty could be applied in the context of HTA and reimbursement decision-making to help manage similar sources of uncertainty.
format Online
Article
Text
id pubmed-10484706
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-104847062023-09-08 What could health technology assessment learn from living clinical practice guidelines? Cheyne, Saskia Chakraborty, Samantha Lewis, Samara Campbell, Sue Turner, Tari Norris, Sarah Front Pharmacol Pharmacology A “living” approach to clinical practice guidelines is when the identification, appraisal and synthesis of evidence is maintained and repeated at an agreed frequency, with a clear process for when and how new evidence is to be incorporated. The value of a living approach to guidelines was emphasised during the COVID-19 pandemic when health professionals and policymakers needed to make decisions regarding patient care in the context of a nascent but rapidly evolving evidence base. In this perspective, we draw on our recent experience developing Australian and international living guidelines and reflect on the feasibility of applying living guideline methods and processes to a lifecycle approach to health technology assessment (HTA). We believe the opportunities and challenges of adopting a living approach in HTA fall into five key themes: identification, appraisal and synthesis of evidence; optimising the frequency of updates; embedding ongoing multi-stakeholder engagement; linking the emergence of new evidence to reimbursement; and system capacity to support a living approach. We acknowledge that the suitability of specific living approaches to HTA will be heavily influenced by the type of health technology, its intended use in the health system, local reimbursement pathways, and other policy settings. But we believe that the methods and processes applied successfully to guideline development to manage evidentiary uncertainty could be applied in the context of HTA and reimbursement decision-making to help manage similar sources of uncertainty. Frontiers Media S.A. 2023-08-24 /pmc/articles/PMC10484706/ /pubmed/37693902 http://dx.doi.org/10.3389/fphar.2023.1234414 Text en Copyright © 2023 Cheyne, Chakraborty, Lewis, Campbell, Turner and Norris. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Cheyne, Saskia
Chakraborty, Samantha
Lewis, Samara
Campbell, Sue
Turner, Tari
Norris, Sarah
What could health technology assessment learn from living clinical practice guidelines?
title What could health technology assessment learn from living clinical practice guidelines?
title_full What could health technology assessment learn from living clinical practice guidelines?
title_fullStr What could health technology assessment learn from living clinical practice guidelines?
title_full_unstemmed What could health technology assessment learn from living clinical practice guidelines?
title_short What could health technology assessment learn from living clinical practice guidelines?
title_sort what could health technology assessment learn from living clinical practice guidelines?
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10484706/
https://www.ncbi.nlm.nih.gov/pubmed/37693902
http://dx.doi.org/10.3389/fphar.2023.1234414
work_keys_str_mv AT cheynesaskia whatcouldhealthtechnologyassessmentlearnfromlivingclinicalpracticeguidelines
AT chakrabortysamantha whatcouldhealthtechnologyassessmentlearnfromlivingclinicalpracticeguidelines
AT lewissamara whatcouldhealthtechnologyassessmentlearnfromlivingclinicalpracticeguidelines
AT campbellsue whatcouldhealthtechnologyassessmentlearnfromlivingclinicalpracticeguidelines
AT turnertari whatcouldhealthtechnologyassessmentlearnfromlivingclinicalpracticeguidelines
AT norrissarah whatcouldhealthtechnologyassessmentlearnfromlivingclinicalpracticeguidelines